- Home
- CYPH vs IBIO Comparison
CYPH vs IBIO Comparison
Compare CYPH & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.94
HOLD
Current Price
$2.19
Company Overview
Basic Information| Metric | CYPH | IBIO |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 72.2M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | CYPH | IBIO |
|---|---|---|
| Price | $0.94 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | ★ 2.1M | 894.2K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.56 |
| 52 Week High | $3.70 | $3.82 |
Technical Indicators
Market Signals| Indicator | CYPH | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 51.61 |
| Support Level | $0.91 | $2.02 |
| Resistance Level | $1.31 | $2.82 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 64.50 | 90.70 |
Price Performance
Historical Comparison CYPH
IBIO
About CYPH Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc is a company developing novel therapies for patients with cancer and implementing a digital asset treasury plan focused on Zcash.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.